Cytiva, a global life sciences company, and NecstGen, have entered a collaboration aiming to accelerate the development of cell and gene therapies globally. Cytiva will provide technologies and services to NecstGen, and both organizations will share their knowledge, expertise, and learnings as research programs are translated into therapies.
Established in 2020, NecstGen is a non-profit CDMO specializing in cell and gene therapies in the Netherlands. It carries out development, production, QC, QA, and QP functions together in a 4000 sqm facility in Leiden Bio Science Park. The facility will serve organisations worldwide, particularly academic and small/large industry enterprises who want to bring their research to the clinical stage. The company will provide process development, cGMP manufacturing services up to 200 L, and cleanroom rental.
Catarina Flyborg, VP, Cell and Gene Therapy, Cytiva said: “Cell and gene therapies are transformative medicines and accelerating their development requires harnessing the power of the industry. By sharing our expertise and providing NecstGen with access to our team of specialists, Cytiva will play a critical role in taking translational research from the laboratory to the bedside.”
Paul Bilars, CEO, NecstGen, said: “Our partnership with Cytiva will provide us with the flexible and scalable solutions needed by pioneers in the field of cell and gene therapy. Working together, we will accelerate the development of future therapies, bringing these to patients faster.”
During the first half of 2021, there were 1,328 regenerative medicine trials underway globally sponsored by non-industry groups such as academic centres and government entities.
